INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Other equities analysts have also recently issued research reports about the stock. Jefferies Financial Group cut shares of INDIVIOR PLC/S from a “buy” rating to a “hold” rating in a research note on Wednesday, November 21st. ValuEngine cut shares of INDIVIOR PLC/S from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 21st.
INDIVIOR PLC/S (OTCMKTS:INVVY) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.40 earnings per share for the quarter. The business had revenue of $245.00 million during the quarter. Research analysts forecast that INDIVIOR PLC/S will post 1.7 earnings per share for the current fiscal year.
INDIVIOR PLC/S Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.